# Grifols SA: overview GRFS · Nasdaq · CIK 1438569 · [Healthcare](/sectors/healthcare.md) Pages: [Overview](/companies/grfs.md) · [Financials](/companies/grfs/financials.md) · [Filings](/companies/grfs/filings.md) · [Insiders](/companies/grfs/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [5,340](/filings/0001104659-23-046470.md) | [4,933](/filings/0001104659-24-049471.md) | [6,064](/filings/0001104659-25-034245.md) | [6,592](/filings/0001104659-25-034245.md) | [7,212](/filings/0001104659-25-034245.md) | | Gross margin | % | [42.2%](/filings/0001104659-23-046470.md) | [39.8%](/filings/0001104659-24-049471.md) | [36.5%](/filings/0001104659-25-034245.md) | [37.7%](/filings/0001104659-25-034245.md) | [38.7%](/filings/0001104659-25-034245.md) | | Operating margin | % | [18.7%](/filings/0001104659-23-046470.md) | [12.1%](/filings/0001104659-24-049471.md) | [12.9%](/filings/0001104659-25-034245.md) | [11.9%](/filings/0001104659-25-034245.md) | [16.5%](/filings/0001104659-25-034245.md) | | Net margin | % | [11.6%](/filings/0001104659-23-046470.md) | [3.8%](/filings/0001104659-24-049471.md) | [3.1%](/filings/0001104659-25-034245.md) | [0.6%](/filings/0001104659-25-034245.md) | [2.2%](/filings/0001104659-25-034245.md) | | Diluted EPS | $ per share | [0.90](/filings/0001104659-23-046470.md) | [0.28](/filings/0001104659-24-049471.md) | [0.27](/filings/0001104659-25-034245.md) | [0.06](/filings/0001104659-25-034245.md) | [0.23](/filings/0001104659-25-034245.md) | | Free cash flow | $m | [830](/filings/0001104659-23-046470.md) | [350](/filings/0001104659-24-049471.md) | [(285)](/filings/0001104659-25-034245.md) | [(5.7)](/filings/0001104659-25-034245.md) | [670](/filings/0001104659-25-034245.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/grfs/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BRANDES INVESTMENT PARTNERS, LP](/funds/1015079.md) | 2026-06-30 | $267.7m | 37,816,285 | | Added +1,482,571 | | [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $162.2m | 22,911,656 | | Reduced −13,334 | | [Permian Investment Partners, LP](/funds/1472850.md) | 2026-06-30 | $139.8m | 19,740,679 | | Added +386,000 | | [Black Creek Investment Management Inc.](/funds/1528593.md) | 2026-06-30 | $54.4m | 7,682,055 | | Reduced −704,397 | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $46.4m | 6,550,337 | | Added +2,222,924 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $30.9m | 4,369,934 | | Reduced −635,598 | | [Flat Footed LLC](/funds/1799456.md) | 2026-06-30 | $30.8m | 4,349,708 | | Added +2,977,314 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $26.4m | 3,290,089 | | Not compared | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $20.9m | 2,958,981 | | Not compared | | [ARMISTICE CAPITAL, LLC](/funds/1601086.md) | 2026-06-30 | $20.8m | 2,936,000 | | Reduced −52,000 | ## Recent filings [All 460 filings](/companies/grfs/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-07-30 | 06:48 ET | [6-K](/filings/0001104659-26-088529.md) | Report of a foreign private issuer, period 2026-07-30 | 0001104659-26-088529 | | 2026-07-29 | 13:41 ET | [6-K](/filings/0001104659-26-087634.md) | Report of a foreign private issuer, period 2026-07-28 | 0001104659-26-087634 | | 2026-06-22 | 10:18 ET | [6-K](/filings/0001104659-26-076294.md) | Report of a foreign private issuer, period 2026-06-22 | 0001104659-26-076294 | | 2026-06-18 | 12:00 ET | [6-K](/filings/0001104659-26-075705.md) | Report of a foreign private issuer, period 2026-06-18 | 0001104659-26-075705 | | 2026-05-15 | 09:13 ET | [6-K](/filings/0001104659-26-062230.md) | Report of a foreign private issuer, period 2026-05-15 | 0001104659-26-062230 | | 2026-05-07 | 10:35 ET | [6-K](/filings/0001104659-26-056966.md) | Report of a foreign private issuer, period 2026-05-07 | 0001104659-26-056966 | | 2026-04-17 | 12:11 ET | [20-F](/filings/0001104659-26-044901.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001104659-26-044901 | | 2026-04-14 | 12:31 ET | [6-K](/filings/0001104659-26-043217.md) | Report of a foreign private issuer, period 2026-04-14 | 0001104659-26-043217 | | 2026-03-24 | 12:55 ET | [6-K](/filings/0001104659-26-033917.md) | Report of a foreign private issuer, period 2026-03-24 | 0001104659-26-033917 | | 2026-02-26 | 11:25 ET | [6-K](/filings/0001104659-26-020526.md) | Report of a foreign private issuer, period 2026-02-26 | 0001104659-26-020526 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-044901.md), filed Apr 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1438569 - Tickers: GRFS, GIFLF, GIFOF, GIKLY - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: not reported - Filer category: Large accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.